Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

Study results demonstrated that among 72 patients lymphoma receiving axicabtagene ciloleucel CAR T-cell therapy—49 with diffuse large B-cell lymphoma—those with circulating tumor DNA (ctDNA) concentrations < 10 or 10-100 lymphoma genomes per mL (LG/mL) pre-lymphodepletion had significantly better progression-free survival and overall survival than those with ctDNA concentrations > 100 LG/mL.